Forbes August 12, 2024
The Food and Drug Administration approved Neffy epinephrine-based nasal spray to treat emergency allergic reactions, including life-threatening anaphylaxis in adults and children, according to an August 9 news release.
Availability of a needle-free epinephrine option—comparable in price to injectables—may reduce barriers to rapid treatment of anaphylaxis, especially for those people who have a fear of injections.
Neffy’s approval was based on four studies that included 175 healthy adults without anaphylaxis. Concentrations of epinephrine in their blood after taking Neffy were comparable to those after using an auto-injector pen, according to the FDA.
The recommended use of Neffy is a single-dose spray of 2mg into one nostril for adults and children who weigh at least 30 kilograms (approximately 66 pounds). If...
Today's Sponsors
Today's Sponsor
